News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.
A female mummy showing anatomical signs of atherosclerotic cardiovascular disease was found to carry risky versions of seven heart disease-related SNPs.
Investigators plan to use the method in future longitudinal monitoring studies based on the sensitivity and ease demonstrated in their early experiments.
The company also announced a deal to provide in-house testing services to drugmaker Biotest, as well as changes to its management team.
